Relevance of an academic GMP Pan-European vector infra-structure (PEVI)

Area of Science:

• Biotechnology
• Gene Therapy
• Clinical Research

Background:

• European investigators have significantly contributed to clinical gene therapy development.
• Increased funding for Good Manufacturing Practice (GMP) facilities presents an opportunity for EU-level networking.
• Coordinating GMP production and expertise is crucial for advanced gene and genetically-modified (GM) cell therapies.

Purpose of the Study:

• To network available gene therapy GMP facilities across the EU.
• To enhance academic-led "First-in-man" gene therapy trials through integrated coordination.
• To facilitate the transfer of proven gene therapy technologies to the private sector.

Main Methods:

• Establishing an integrated coordination of GMP production facilities and human skills.
• Adapting existing facilities to emerging technologies in a coordinated manner.
• Conducting pre-normative research to develop standard assays, processes, and reference materials.

Main Results:

• A consensus on directions and priorities for advanced technologies (AAV, lentivirus, oncolytic vectors) has been reached.
• Harmonization of practices and quality in GMP vector lot and GM-cell production is being facilitated.
• The PEVI infrastructure aims to gather critical expertise and establish interoperability.

Conclusions:

• Coordinated GMP production and expertise sharing can significantly enhance early-phase gene therapy trials.
• Standardized assays and processes are essential for harmonizing quality in vector and cell production.
• The PEVI infrastructure will support advanced therapy medicinal products regulation and improve EU citizens' health.